Overview: Inv 16 Qualitative PCR TestIntroduction: The Inv 16 Qualitative PCR Test detects the inv(16) gene rearrangement to diagnose acute myeloid leukemia (AML), causing fatigue or bleeding. Aligned with 2023 WHO guidelines, it uses polymerase chain reaction (PCR) for high specificity, supporting cancer screening. This test is critical for guiding diagnosis, treatment planning, and improving outcomes in molecular pathology for patients with suspected AML.
Other Names: Inv 16 Qual PCR Assay, AML Inv 16 Test.
FDA Status: Laboratory-developed test (LDT), meeting molecular pathology standards for diagnostic accuracy.
Historical Milestone: Inv(16) testing began in the 1990s with AML research. PCR-based methods improved in the 2000s, enhancing diagnostic precision for core-binding factor AML.
Purpose: Detects inv(16) gene rearrangement to diagnose AML, guides treatment, and evaluates patients with fatigue or bleeding.
Test Parameters: 1. Inv 16 Gene Rearrangement
Pretest Condition: No fasting required. Collect whole blood, bone marrow, or saliva. Report history of fatigue, bleeding, or leukemia symptoms.
Specimen: Whole Blood (EDTA, 2-5 mL), Bone Marrow (EDTA, 2-5 mL), Saliva (sterile container, 1-2 mL). Transport in a biohazard container.
Sample Stability at Room Temperature: 24 hours
Sample Stability at Refrigeration: 48 hours
Sample Stability at Frozen: Not frozen
Medical History: Document fatigue, bruising, infections, or family history of leukemia. Include current medications, especially chemotherapy.
Consent: Written consent required, detailing the tests purpose, leukemia implications, and risks of blood or bone marrow collection.
Procedural Considerations: Uses qualitative PCR to detect inv(16) in whole blood, bone marrow, or saliva. Results are available in 3-5 days, supporting clinical decisions. Performed in laboratories, often for AML diagnosis.
Factors Affecting Result Accuracy: Improper sample storage or contamination can affect results. Low DNA yield may reduce sensitivity.
Clinical Significance: Positive inv(16) confirms core-binding factor AML, guiding chemotherapy or transplant. Negative results may require further genetic testing.
Specialist Consultation: Consult a hematologist or oncologist for result interpretation and treatment planning.
Additional Supporting Tests: CBFβ-MYH11 fusion, flow cytometry, or bone marrow biopsy to confirm AML diagnosis.
Test Limitations: Not specific to all AML subtypes; clinical correlation is needed. Rare variants may not be detected.
References: WHO Hematopathology Guidelines, 2023; Blood, Arber DA, 2022.
